avanafil (Stendra)
Jump to navigation
Jump to search
Indications
- treatment of erectile dysfunction
Contraindications
Dosage
- 50-200 mg 30 minutes prior to sexual activity
Pharmacokinetics
Adverse effects
- drug adverse effects of phosphodiesterase-5-inhibitors
- drug adverse effects of antihypertensive agents
Drug interactions
- hypotension in combination with nitrates
- prone to CYP3A4 interactions[2]
- avoid it with strong inducers of CYP3A4 (phenytoin) or strong inhibitors (itraconazole)
- drug interaction(s) of nitrates with phosphodiesterase-5-inhibitors
- drug interaction(s) of phosphodiesterase-5-inhibitor with testosterone
- drug interaction(s) of phosphodiesterase-5-inhibitor with nitrates
- drug interaction(s) of phosphodiesterase-5-inhibitors with alpha-1-adrenergic receptor antagonists
- drug interaction(s) of NSAIDs & antihypertensives
More general terms
References
- ↑ FDA News Release: April 27, 2012 FDA approves Stendra for erectile dysfunction http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140.htm
- ↑ 2.0 2.1 Prescriber's Letter 21(4): 2014 Comparison of PDE5 Inhibitors Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300408&pb=PRL (subscription needed) http://www.prescribersletter.com